<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0003623'>Neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> is characterized by <z:hpo ids='HP_0001945'>fever</z:hpo>, <z:e sem="disease" ids="C0042109" disease_type="Disease or Syndrome" abbrv="">urticarial rash</z:e>, aseptic <z:hpo ids='HP_0001287'>meningitis</z:hpo>, deforming <z:hpo ids='HP_0003040'>arthropathy</z:hpo>, hearing loss, and <z:hpo ids='HP_0001249'>mental retardation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Many patients have mutations in the cold-induced autoinflammatory syndrome 1 (CIAS1) gene, encoding cryopyrin, a protein that regulates <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We selected 18 patients with <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> (12 with identifiable CIAS1 mutations) to receive anakinra, an interleukin-1-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (1 to 2 mg per kilogram of body weight per day subcutaneously) </plain></SENT>
<SENT sid="3" pm="."><plain>In 11 patients, anakinra was withdrawn at three months until a flare occurred </plain></SENT>
<SENT sid="4" pm="."><plain>The primary end points included changes in scores in a daily diary of symptoms, serum levels of amyloid A and C-reactive protein, and the erythrocyte sedimentation rate from baseline to month 3 and from month 3 until a disease flare </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> 18 patients had a rapid response to anakinra, with disappearance of <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Diary scores improved (P&lt;0.001) and serum amyloid A (from a median of 174 mg to 8 mg per liter), C-reactive protein (from a median of 5.29 mg to 0.34 mg per deciliter), and the erythrocyte sedimentation rate decreased at month 3 (<z:hpo ids='HP_0000001'>all</z:hpo> P&lt;0.001), and remained low at month 6 </plain></SENT>
<SENT sid="7" pm="."><plain>Magnetic resonance imaging showed improvement in cochlear and leptomeningeal lesions as compared with baseline </plain></SENT>
<SENT sid="8" pm="."><plain>Withdrawal of anakinra uniformly resulted in relapse within days; retreatment led to rapid improvement </plain></SENT>
<SENT sid="9" pm="."><plain>There were no drug-related serious adverse events </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Daily injections of anakinra markedly improved clinical and laboratory manifestations in patients with <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e>, with or without CIAS1 mutations </plain></SENT>
<SENT sid="11" pm="."><plain>(ClinicalTrials.gov number, NCT00069329 [ClinicalTrials.gov].) </plain></SENT>
</text></document>